Targanta Therapeutics (TARG) Sees IPO Price of $12-$14
More News related to TARG
- Medicines Company (MDCO) Commences Tender Offer for Targanta Therapeutics (TARG)
- Unusual 11 Mid-Day Movers 1/13: TARG, ZGEN, FIG, LXP Higher; BQI, RMBS, CPHD, LXK Lower
- Morning Movers 1/13: ZymoGenetics (ZGEN) Up On Bristol-Myers Deal; Lexmark (LXK) Down On Guidance
- The Medicines Co (MDCO) Acquires Targanta Therapeutics (TARG) For $2/Share
- Unusual 11 Mid-Day Movers 12/09: DRYS, CPE, XCO, EXM Higher; TARG, TRGT, ALOG, PBY Lower
Targanta Therapeutics (Nasdaq: TARG) has filed an amended registration statement with the SEC for an initial public offering of its common stock. The Company is offering 5.75 million shares and expects the offering price to be between $12-$14 per share. The Company plans to list on the NASDAQ under the symbol "TARG".
The offering is being made through Credit Suisse, Cowen & Co, Lazard Capital Markets and Leerink Swann.
Targanta is a biopharmaceutical company focused on the development and commercialization of innovative antibiotics for serious infections treated or acquired in hospitals and other institutional settings. The company is developing oritavancin, a novel intravenous antibiotic, for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections, or cSSSI, and bacteremia, an infection caused by bacteria in the bloodstream.
Related Categories
IPOsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
